Application of Real-Time Quantitative PCR to Molecular Analysis of Candida albicans Strains Exhibiting Reduced Susceptibility to Azoles
Open Access
- 1 June 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (6), 2124-2131
- https://doi.org/10.1128/aac.48.6.2124-2131.2004
Abstract
Real-time quantitative PCR was used to measure expression levels of genes encoding efflux pumps, ERG11 and two control genes, ACT1 and PMA1, in a collection of 14 fluconazole-susceptible Candida albicans isolates. For each gene, average expression levels and variations within the population were determined. These values were then used as reference points to make predictions about the molecular basis of resistance in 38 clinical isolates (the majority of which were resistant to fluconazole) obtained from 18 patients treated with posaconazole for refractory oropharyngeal candidiasis. For each of the 38 isolates, the expression levels of genes encoding efflux pumps, ERG11 and the control genes, were measured as above. Comparison of the two data sets revealed that expression of ACT1 and PMA1 did not vary significantly between the two sets of isolates. In contrast, MDR1, ERG11, CDR1, and CDR2 were overexpressed in 3, 4, 14, and 35, respectively, of the isolates from patients treated with azoles. In addition to these changes, the patient isolates all had at least one and often multiple missense mutations in ERG11. Select ERG11 alleles were expressed in Saccharomyces cerevisiae; all of the alleles tested conferred reduced susceptibility to fluconazole. Despite both the increases in pump expression and the ERG11 mutations, only one of the patient isolates exhibited a large decrease in posaconazole susceptibility.Keywords
This publication has 19 references indexed in Scilit:
- Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole BindingAntimicrobial Agents and Chemotherapy, 2004
- Changes in susceptibility to posaconazole in clinical isolates of Candida albicansJournal of Antimicrobial Chemotherapy, 2003
- Molecular Mechanisms of Fluconazole Resistance in Candida dubliniensis Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal CandidiasisAntimicrobial Agents and Chemotherapy, 2002
- Resistance Mechanisms in Clinical Isolates of Candida albicansAntimicrobial Agents and Chemotherapy, 2002
- A common drug‐responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistanceMolecular Microbiology, 2002
- In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2001
- Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2001
- Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transportersAntimicrobial Agents and Chemotherapy, 1995
- CandidiasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- Anti-CandidaDrugs — The Biochemical Basis for Their ActivityCRC Critical Reviews in Microbiology, 1987